ClinicalTrials.gg
CompletedNCT04879368INTEGRATEIIbUpdated Jun 10, 2026Results posted

RegoNivo vs Standard of Care Chemotherapy in AGOC

A Phase 3 interventional study of Regorafenib and Nivolumab in Gastro-Oesophageal Cancer, sponsored by Australasian Gastro-Intestinal Trials Group. Completed at 94 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Australasian Gastro-Intestinal Trials Group · Phase 3, Interventional, and Treatment

How we know · 13 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
462
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing regorafenib in Neoplasm Metastasis — 2 open to participants now, 2 under way, none of them phase 3. regorafenib · Neoplasm Metastasis.

Enrollment
2nd of 17
462 · median 50
Started
2021
the only one that year
Phase 3
3 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
2 of 17
Australasian Gastro-Intestinal Trials Group

Among the 17 studies testing regorafenib in Neoplasm Metastasis, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 16th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

2 of the 17 studies testing regorafenib in Neoplasm Metastasis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing regorafenib in Neoplasm Metastasis, or all of them as a file.
02

Study summary

To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.

Read the detailed description

The purpose of this international study is to determine if the combination of regorafenib and nivolumab is more effective than standard chemotherapy in prolonging overall survival in a broad group of participants with AGOC, who have progressed after treatment with standard anti-cancer therapy.

In the INTEGRATE study, regorafenib alone was shown to be effective in prolonging the progression-free period in people with AGOC following standard anti-cancer therapy (i.e. it delayed tumour growth), and demonstrated a potential benefit on long term survival. Recent research has shown the early results from this combination of regorafenib \& nivolumab may improve outcomes for cancer patients. INTEGRATE IIb will investigate this effect further in a larger group of participants with AGOC.

The study aims to determine:

i. Whether the combination of regorafenib/nivolumab is likely to help patients with AGOC live longer; ii. The effects of this treatment on progression-free survival; iii. The numbers of participants responding to the treatment iv. The effects of this treatment on quality of life v. The side effects and tolerability of this treatment vi. Molecular differences (e.g. variations in genes or proteins) that may account for the effects of this treatment vii. Differences in the costs of care for people on this treatment.

The Investigators plan to enrol 460 participants in the study from, but not limited to; Australia, South Korea, Japan, Taiwan, USA, Germany, Austria, Spain, and Italy.

03

Conditions studied

  • Gastro-Oesophageal Cancer

Keywords

  • Metastatic
  • Locally recurrent
  • Oesophago-gastric junction
  • Stomach
  • Adenocarcinoma
  • Undifferentiated carcinoma
  • RegoNivo
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (18 years or over) with or locally recurrent gastro-oesophageal cancer which:

    1. has arisen in any primary gastro-oesophageal site (oesophago-gastric junction (GOJ) or stomach); and
    2. is of adenocarcinoma or undifferentiated carcinoma histology; and
    3. is evaluable according to (RECIST Version 1.1) by computed tomography (CT) scan performed within 21 days prior to randomisation. A lesion in a previously irradiated area is eligible to be considered as as long as there is objective evidence of progression of the lesion prior to study enrolment; and
    4. has failed or been intolerant to a minimum of 2 lines of prior anti-cancer therapy for recurrent/metastatic disease which must have included at least one platinum agent and one fluoropyrimidine analogue. Note: or adjuvant chemotherapy or chemoradiotherapy will be considered as treatment where people have or progressed within 6 months of completing treatment; Radiosensitising chemotherapy given solely for this purpose concurrent with palliative radiation will not be considered as a line of treatment. Ramucirumab monotherapy, or immunotherapy with a , will be considered a line of treatment.
    5. -positive participants must have received trastuzumab
  2. (ECOG) Performance Status of 0 or 1 (Appendix 1).
  3. Ability to swallow oral medication.
  4. Adequate bone marrow function ( ≥100x109/L; (ANC) ≥1.5x109/L and ≥ 9.0g/dL).
  5. Adequate renal function ( >50 ml/min) based on either the Cockcroft-Gault formula (Appendix 2), 24-hour urine or (GFR) scan; and serum creatinine ≤1.5 x (ULN).
  6. Adequate liver function (Serum total ≤1.5 x ULN, and ≤ 1.5 x ULN, and (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤2.5 x ULN (≤ 5 x ULN for participants with liver metastases)).

    Participants being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to participate provided that no prior evidence of an underlying abnormality in these parameters exists.

  7. Willing and able to comply with all study requirements, including treatment, timing, and/or nature of required assessments and follow-up.
  8. Study treatment both planned and able to start within 7 days after randomisation (note: subjects randomised on a Friday should commence treatment no earlier than the following Monday)
  9. Signed, written

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to the product drug class or in the regorafenib and/or nivolumab
  2. Poorly-controlled hypertension (systolic blood pressure >140mmHg or diastolic pressure> 90mmHg despite optimal medical management).
  3. Participants with known, uncontrolled malabsorption syndromes
  4. Any prior anti-VEGF targeted therapy using small molecule VEGF TKIs (e.g. apatinib). Prior anti-VEGF targeted monoclonal antibody therapies (e.g. bevacizumab and ramucirumab) are permitted.
  5. Any prior use of more than one
  6. Treatment with any previous drug therapy within 2 weeks prior to first dose of study treatment. This includes any investigational therapy.
  7. Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks prior to randomisation.
  8. Concurrent treatment with strong inhibitors or inducers.
  9. Palliative radiotherapy, unless more than 14 days have elapsed between completion of radiation and the date of registration, and adverse events resulting from radiation have resolved to \< Grade 2 according to V5.0
  10. Major surgical procedure, open , or significant traumatic injury within 28 days prior to randomization
  11. Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6 months prior to randomization.
  12. Venous thrombotic events and pulmonary embolism within 3 months prior to randomization
  13. Any haemorrhage or bleeding event ≥ Grade 3 according to CTCAE v5.0 within 4 weeks prior to randomization.
  14. Non-healing wound, ulcer, or bone fracture.
  15. Interstitial lung disease with ongoing signs and symptoms
  16. Clinical hyperthyroidism or hypothyroidism. Note: non- abnormal TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick euthyroid syndrome is allowed.
  17. Persistent proteinuria of ≥ Grade 3 according to CTCAE v5.0 (equivalent to > 3.5g of protein over 24 hour measured on either a random specimen or 24 hour collection.
  18. Uncontrolled disease to the central nervous system. To be eligible, known should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of for at least 2 weeks prior to randomization, with no deterioration in neurological symptoms during this time.
  19. History of another within 2 years prior to randomization. Participants with the following are eligible for this study:

    1. curatively treated cervical carcinoma in situ,
    2. non-melanomatous carcinoma of the skin,
    3. superficial bladder tumours (T1a [Non-invasive tumour], and Tis [Carcinoma in situ]),
    4. treated thyroid papillary cancer
  20. Any significant active infection, including chronic active , , or . Testing for these is not mandatory unless clinically indicated. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
  21. Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrolment
  22. Patients with a ≥ grade 3 active infection according to CTCAE version 5.0
  23. Patients with concurrent disease, or a history of chronic or recurrent autoimmune disease
  24. Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy; if used as replacement therapy e.g. ≤ 10 mg prednisolone or dexamethasone ≤ 2 mg per day) or , or who have received such a therapy \< 14 days prior to randomisation
  25. Patients with a seizure disorder who require pharmacotherapy
  26. Serious medical or psychiatric condition(s) that might limit the ability of the patient to comply with the protocol.
  27. Pregnancy, lactation, or inadequate . Women must be infertile, or use a reliable means of contraception. Women of must have a negative pregnancy test done within 7 days prior to randomization. Men must have been surgically sterilized or use a barrier method of contraception.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
462 participants (actual)

Study arms

  • Experimental
    RegoNivo

    Participants in the RegoNivo arm will; 1. self-administer 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle and; 2. receive intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol, given in hospital by infusion. After 2 months, patients whose disease is controlled may have nivolumab administered 480 mg every 28 days.

    Drug: Regorafenib · Biological: Nivolumab

  • Active comparator
    Standard of Care

    Participants in the control arm will receive investigator choice chemotherapy with any of the following agents * taxane (paclitaxel or docetaxel) * irinotecan or * oral trifluridine/tipiracil (TAS102) All treatment groups will receive Best Supportive Care (BSC).

    Drug: Docetaxel · Drug: Paclitaxel · Drug: Irinotecan · Drug: Trifluridine/Tipracil

Interventions

  • Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases

    Also known as: Stivarga

  • BiologicalNivolumab

    human IgG4 monoclonal antibody inhibitor of PD-1

    Also known as: Opdivo

  • Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc. microtubules, and simultaneously promotes assembly and inhibits disassembly of them

    Also known as: Taxotere

  • Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division

    Also known as: Abraxane

  • Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.

    Also known as: Camptosar

  • DrugTrifluridine/Tipracil

    The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.

    Also known as: Lonsurf

06

What researchers measure

Primary outcomes

  1. O/S

    To determine the effect of RegoNivo on overall survival (OS) (death from any cause) in the overall study population and in the Asian sub-population. Overall survival is defined as the interval from the date of randomisation to date of death from any cause, or the date last known alive.

    Time frame: From the date of randomisation to date of death from any cause or the date last known alive, assessed up to approximately 44 months.

Secondary outcomes

  1. Determine the Effect of RegoNivo on; PFS

    A PFS (Progressive free survival) event is defined as the first occasion that either RECIST criteria and iRECIST for disease progression are met, a patient is judged to have progressed by the responsible investigator (in the event that no RECIST assessment is available) or death occurs. Progression is defined using RECIST v1.1 and iRECIST, as a 20% increase in the sum of the longest diameter of target lesions taking as reference the smallest sum of diameters recorded in the study (including baseline) and an absolute increase of at least 5mm. The appearance of one or more new lesions is also considered progression. In exceptional circumstances, unequivocal progression of non-target disease was accepted as evidence of disease progression, where the overall tumour burden has increased sufficiently to merit discontinuation of treatment or where the tumour burden appears to have increased by at least 73% in volume.

    Time frame: From the date of randomisation to the date of first evidence of disease progression or death, whichever occurs first, assessed up to approximately 44 months.

  2. Determine the Effect of RegoNivo on; OTRR

    Number of participants achieving a Partial Response (PR) or Complete Response (CR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and iRECIST. Complete Response (CR): Disappearance of all target and non-target lesions and normalisation of any specified tumour markers Partial Response (PR): \>=30% decrease in the sum of diameters of target lesions (longest diameter for tumour lesions and short axis measure for target lymph nodes), taking as reference the baseline sum of diameters.

    Time frame: From randomisation until disease progression, with tumour assessments performed every 8 weeks (±7 days), assessed up to approximately 44 months.

  3. Deterioration-Free Survival (DFS) Based on Physical Function (EORTC QLQ-C30)

    Quality of life (scores from participant-completed questionnaires) of participants on study EORTC QoL Questionnaire: QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse QLQ-C30: Q29 \& Q30 Min 1 Max 7, Higher = Better Deterioration-Free Survival (DFS) rate based on Physical Function is defined as the percentage of participants who have not experienced deterioration, disease progression, death, or treatment discontinuation at the specified time point. Deterioration is defined as a ≥10-point decrease from baseline in the Physical Function scale of the EORTC QLQ-C30, without a subsequent ≥10-point improvement compared with baseline. Physical function is assessed using the EORTC QLQ-C30 Physical Function Scale to identify the percentage of participants who were deterioration-free at 6 months and 12 months.

    Time frame: 6 months and 12 months after randomisation.

  4. Deterioration-Free Survival Rate Based on Global Health Status (EORTC QLQ-C30)

    Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC Quality of Life Questionnaire: EORTC QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse EORTC QLQ-C30: Q29 \& Q30 Min 1 Max 7, Higher = Better Deterioration-Free Survival (DFS) rate based on Global Health Status is defined as the percentage of participants who have not experienced any of the following events by the specified time point; A ≥10-point deterioration from baseline in the Global Health Status/QoL scale of the EORTC QLQ-C30, without a subsequent ≥10-point improvement, disease progression, death from any cause or treatment discontinuation. Global Health Status is assessed using the EORTC QLQ-C30 Global Health Status to identify the percentage of participants who were deterioration free at 6 months and 12 months.

    Time frame: 6 months and 12 months after randomisation

  5. Determine the Effect of RegoNivo on; Safety

    Safety (rates of adverse events) of participants on study

    Time frame: From the first dose of study treatment until 30 days following the last dose of study treatment, up to approximately 44 months.

Other outcomes

  1. Prognostic Biomarker Identification for AGOC

    To identify prognostic and predictive biomarkers (tissue and circulating) for study endpoints (relating to survival, response and safety).

    Time frame: Up to 24 months following close of study.

  2. Regorafenib Max Plasma Concentration Level Assessment (Cmax) Across Geographical Regions

    To evaluate regorafenib Cmax in patient populations from different geographical regions (regorafenib levels).

    Time frame: Up to 24 months following close of study.

  3. Regorafenib Levels and Correlation to Treatment

    To evaluate regorafenib levels and their correlation to outcomes in treatment

    Time frame: Up to 24 months following close of study.

07

Results

Posted Jun 10, 2026

Participant flow

Participants were recruited from 73 clinical sites across Austria, Australia, Germany, Italy, Japan, Spain, South Korea, Taiwan and United States of America. Eligibility was confirmed through screening visits, and informed consent was obtained prior to any study procedures. Randomisation occurred between 05/05/2021 and 30/04/2024.

Participant flow — Overall Study
MilestoneRegoNivoStandard of Care
Started309153
Completed291129
Not completed1824

Outcome measures

PrimaryO/S

To determine the effect of RegoNivo on overall survival (OS) (death from any cause) in the overall study population and in the Asian sub-population. Overall survival is defined as the interval from the date of randomisation to date of death from any cause, or the date last known alive.

Time frame:
From the date of randomisation to date of death from any cause or the date last known alive, assessed up to approximately 44 months.
Reported as:
Median · Months
O/S
MonthsRegoNivoStandard of Care
O/S5.91 (5.16 to 6.80)6.28 (4.80 to 7.36)
Statistical analysis
  • RegoNivo vs Standard of Care · Stratified log-rank test · p = 0.23 (Two-sided α = 0.05. P-value adjusted using a sequential closed testing procedure for multiple comparisons.) · Hazard ratio (hr): 0.88 · 95% CI 0.71 to 1.09Hazard ratio estimated using a stratified Cox proportional hazards model comparing regorafenib plus nivolumab versus chemotherapy.
SecondaryDetermine the Effect of RegoNivo on; PFS

A PFS (Progressive free survival) event is defined as the first occasion that either RECIST criteria and iRECIST for disease progression are met, a patient is judged to have progressed by the responsible investigator (in the event that no RECIST assessment is available) or death occurs. Progression is defined using RECIST v1.1 and iRECIST, as a 20% increase in the sum of the longest diameter of target lesions taking as reference the smallest sum of diameters recorded in the study (including baseline) and an absolute increase of at least 5mm. The appearance of one or more new lesions is also considered progression. In exceptional circumstances, unequivocal progression of non-target disease was accepted as evidence of disease progression, where the overall tumour burden has increased sufficiently to merit discontinuation of treatment or where the tumour burden appears to have increased by at least 73% in volume.

Time frame:
From the date of randomisation to the date of first evidence of disease progression or death, whichever occurs first, assessed up to approximately 44 months.
Reported as:
Median · Months
Determine the Effect of RegoNivo on; PFS
MonthsRegoNivoStandard of Care
Determine the Effect of RegoNivo on; PFS1.91 (1.84 to 2.04)1.87 (1.77 to 2.00)
Statistical analysis
  • RegoNivo vs Standard of Care · Hazard ratio (hr): 0.85 · 95% CI 0.69 to 1.05Hazard ratio estimated using a stratified Cox proportional hazards model comparing regorafenib plus nivolumab versus chemotherapy
SecondaryDetermine the Effect of RegoNivo on; OTRR

Number of participants achieving a Partial Response (PR) or Complete Response (CR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and iRECIST. Complete Response (CR): Disappearance of all target and non-target lesions and normalisation of any specified tumour markers Partial Response (PR): \>=30% decrease in the sum of diameters of target lesions (longest diameter for tumour lesions and short axis measure for target lymph nodes), taking as reference the baseline sum of diameters.

Time frame:
From randomisation until disease progression, with tumour assessments performed every 8 weeks (±7 days), assessed up to approximately 44 months.
Reported as:
Number · Number of participants with CR or PR
Determine the Effect of RegoNivo on; OTRR
Number of participants with CR or PRRegoNivoStandard of Care
Determine the Effect of RegoNivo on; OTRR234
Statistical analysis
  • RegoNivo vs Standard of Care · Odds ratio (or): 2.99 · 95% CI 1.00 to 12.11Odds ratio estimated using Cochran-Mantel-Haenszel test comparing regorafenib plus nivolumab versus chemotherapy.
SecondaryDeterioration-Free Survival (DFS) Based on Physical Function (EORTC QLQ-C30)

Quality of life (scores from participant-completed questionnaires) of participants on study EORTC QoL Questionnaire: QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse QLQ-C30: Q29 \& Q30 Min 1 Max 7, Higher = Better Deterioration-Free Survival (DFS) rate based on Physical Function is defined as the percentage of participants who have not experienced deterioration, disease progression, death, or treatment discontinuation at the specified time point. Deterioration is defined as a ≥10-point decrease from baseline in the Physical Function scale of the EORTC QLQ-C30, without a subsequent ≥10-point improvement compared with baseline. Physical function is assessed using the EORTC QLQ-C30 Physical Function Scale to identify the percentage of participants who were deterioration-free at 6 months and 12 months.

Time frame:
6 months and 12 months after randomisation.
Reported as:
Number · Percentage of participants
Deterioration-Free Survival (DFS) Based on Physical Function (EORTC QLQ-C30)
Percentage of participantsRegoNivoStandard of Care
DFS Rate at 6 Months (Physical Function)6.9 (4.4 to 10)6.3 (3.1 to 11)
DFS Rate at 12 Months (Physical Function)3.9 (2.1 to 6.5)0.7 (0.1 to 3.5)
Statistical analysis
  • RegoNivo vs Standard of Care · Hazard ratio (hr): 0.86 · 95% CI 0.70 to 1.05Hazard ratio estimated using a stratified Cox proportional hazards model comparing regorafenib plus nivolumab versus chemotherapy.
SecondaryDeterioration-Free Survival Rate Based on Global Health Status (EORTC QLQ-C30)

Quality of life (QoL)(scores from participant-completed questionnaires) of participants on study EORTC Quality of Life Questionnaire: EORTC QLQ-C30: Q1 - Q28, Min 1 Max 4, Higher Score = Worse EORTC QLQ-C30: Q29 \& Q30 Min 1 Max 7, Higher = Better Deterioration-Free Survival (DFS) rate based on Global Health Status is defined as the percentage of participants who have not experienced any of the following events by the specified time point; A ≥10-point deterioration from baseline in the Global Health Status/QoL scale of the EORTC QLQ-C30, without a subsequent ≥10-point improvement, disease progression, death from any cause or treatment discontinuation. Global Health Status is assessed using the EORTC QLQ-C30 Global Health Status to identify the percentage of participants who were deterioration free at 6 months and 12 months.

Time frame:
6 months and 12 months after randomisation
Reported as:
Number · Percentage of participants
Deterioration-Free Survival Rate Based on Global Health Status (EORTC QLQ-C30)
Percentage of participantsRegoNivoStandard of Care
DFS Rate at 6 Months (Global Health Status)6.9 (4.4 to 10)5.6 (2.6 to 10)
DFS Rate at 12 Months (Global Health Status)3.9 (2.1 to 6.5)0.7 (0.1 to 3.5)
Statistical analysis
  • RegoNivo vs Standard of Care · Hazard ratio (hr): 0.74 · 0.6% CI 0.60 to 0.91Hazard ratio estimated using a stratified Cox proportional hazards model comparing regorafenib plus nivolumab versus chemotherapy.
Other pre-specifiedPrognostic Biomarker Identification for AGOC

To identify prognostic and predictive biomarkers (tissue and circulating) for study endpoints (relating to survival, response and safety).

Time frame:
Up to 24 months following close of study.

Results for this outcome have not been posted.

Other pre-specifiedRegorafenib Max Plasma Concentration Level Assessment (Cmax) Across Geographical Regions

To evaluate regorafenib Cmax in patient populations from different geographical regions (regorafenib levels).

Time frame:
Up to 24 months following close of study.

Results for this outcome have not been posted.

Other pre-specifiedRegorafenib Levels and Correlation to Treatment

To evaluate regorafenib levels and their correlation to outcomes in treatment

Time frame:
Up to 24 months following close of study.

Results for this outcome have not been posted.

SecondaryDetermine the Effect of RegoNivo on; Safety

Safety (rates of adverse events) of participants on study

Time frame:
From the first dose of study treatment until 30 days following the last dose of study treatment, up to approximately 44 months.
Reported as:
Count of participants · Participants
Determine the Effect of RegoNivo on; Safety
ParticipantsRegoNivoStandard of Care
Any AE (Grade 1-5)293127
Any SAE (Grade 1-5)12234

Adverse events

Collected over From the first dose of study treatment until 30 days following the last dose of study treatment, up to approximately 44 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RegoNivo262/309 (84.8%)122/300 (40.7%)293/300 (97.7%)
Standard of Care128/153 (83.7%)34/138 (24.6%)127/138 (92%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventRegoNivoStandard of Care
General disorders totalGastrointestinal disorders38/30012/138
General disorders totalInfections and infestations26/3006/138
General disorders totalGeneral disorders17/3003/138
General disorders totalRespiratory, thoracic and mediastinal disorders14/3005/138
General disorders totalSkin and subcutaneous tissue disorders12/3000/138
General disorders totalInvestigations8/3004/138
General disorders totalHepatobiliary disorders8/3001/138
General disorders totalMetabolism and nutrition disorders8/3003/138
General disorders totalBlood and lymphatic system disorders4/3003/138
General disorders totalMusculoskeletal and connective tissue disorders5/3000/138
Most frequent other events
Showing 10 of 26
Most frequent other events
EventRegoNivoStandard of Care
General disorders totalGastrointestinal disorders185/30091/138
General disorders totalGeneral disorders146/30055/138
General disorders totalInvestigations135/30060/138
General disorders totalSkin and subcutaneous tissue disorders121/30021/138
General disorders totalMetabolism and nutrition disorders106/30039/138
General disorders totalRespiratory, thoracic and mediastinal disorders84/30018/138
General disorders totalBlood and lymphatic system disorders46/30037/138
General disorders totalInfections and infestations68/30025/138
General disorders totalVascular disorders66/30010/138
General disorders totalMusculoskeletal and connective tissue disorders62/30017/138

Baseline characteristics

The baseline analysis participants matches the participant flow count

Sex: Female, Male
Sex: Female, Male(Participants)RegoNivoStandard of CareTotal
Female8339122
Male226114340
Prior use of VEGF inhibitors
Prior use of VEGF inhibitors(Participants)RegoNivoStandard of CareTotal
Number19090280
Age, Customized
Age, Customized(Participants)RegoNivoStandard of CareTotal
<=6417382255
>6413671207
Prior immunotherapy
Prior immunotherapy(Participants)RegoNivoStandard of CareTotal
Number10250152
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RegoNivoStandard of CareTotal
Asia14773220
Rest of the world16280242
08

Study locations

94 sites
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85054, United States
  • USC Norris
    Los Angeles, California 90001, United States
  • Siouxland Regional Cancer Center
    Sioux City, Iowa 51101, United States
  • St Elizabeth Healthcare
    Edgewood, Kentucky 41017, United States
  • Monument Health Rapid City Hospital
    Rapid City, South Dakota 57701, United States
  • Fred Hutchinson Cancer Research Centre - South Lake Union Clinic
    Seattle, Washington 98109, United States
  • Coffs Harbour Health Campus
    Coffs Harbour, New South Wales 2450, Australia
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • St Vincent's Public Hospital
    Darlinghurst, New South Wales 2010, Australia
  • Border Medical Oncology Research Unit
    East Albury, New South Wales 2640, Australia
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Newcastle Private Hospital
    New Lambton Heights, New South Wales 2035, Australia
  • Port Macquarie Base Hospital
    Port Macquarie, New South Wales 2444, Australia
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Royal North Shore Private Hospital
    Sydney, New South Wales 2065, Australia
  • The Tweed Hospital
    Tweed Heads, New South Wales 2485, Australia
  • Ballarat Oncology and Haematology Services
    Wendouree, New South Wales 3355, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Darwin Hospital
    Tiwi, Northern Territory 0810, Australia
  • The Townsville Hospital
    Douglas, Queensland 4814, Australia
  • Royal Brisbane and Womens Hospital
    Herston, Queensland 4029, Australia
  • Sunshine Coast University Hospital
    Sunshine Coast, Queensland 4560, Australia
  • The Queen Elizabeth Hospital
    Adelaide, South Australia 5011, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 700, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Austin Health
    Melbourne, Victoria 3084, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • St John of God Hospital Subiaco
    Subiaco, Western Australia 6008, Australia
  • Landeskrankenanstalten-Betriebsgesellschaft-KABEG
    Klagenfurt, Austria
  • Ordensklinikum Linz GmbH Barmherzige schwestern
    Linz, Austria
  • Medizinische Universitaet Wien
    Vienna, Austria
  • Landesklinikum Wiener Neustadt
    Wiener Neustadt, Austria
  • Evang. Klinikum Bethel Bielefeld
    Gütersloh, North Rhine-Westphalia, Germany
  • Helios Bad Saarow
    Bad Saarow, Germany
  • Klinikum Bayreuth
    Bayreuth, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, Germany
  • Universitätsklinikum Bonn
    Bonn, Germany
  • Kliniken der Stadt Köln
    Cologne, Germany
  • KEM/Evang. Kliniken Essen Mitte gGmbH
    Essen, Germany
  • Institut für Klinisch Onkol Forschung am Krankenhaus Nordwest
    Frankfurt, Germany
  • Universitätsklinikum Greifswald
    Greifswald, Germany
  • Norddeutsches Studienzentrum für Innovative Onkologie (NIO)
    Hamburg, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, Germany
  • Universitätsklinikum Jena
    Jena, Germany
  • Universitätsklinikum Leipzig
    Leipzig, Germany
  • Klinikum Leverkusen gGmbH
    Leverkusen, Germany
  • Klinikum Ludwigburg
    Ludwigsburg, Germany
  • Klinikum Magdeburg gGmbH
    Magdeburg, Germany
  • Universitätsklinikum Mainz
    Mainz, Germany
  • Philipps-Universitat Marburg
    Marburg, Germany
  • Klinikum rechts der Isar der TU München
    München, Germany
  • Studienzentrum Onkologie Ravensburg
    Ravensburg, Germany
  • Caritas Klinikum Saarbrücken St. Theresia
    Saarbrücken, Germany
  • Universitätsklinikum Ulm
    Ulm, Germany
  • Istituto Nazionale Tumori di Napoli-IRCCS Fondazione G. Pascale
    Naples, Italy
  • Universitae degli studi della Campania "Luigi Vanvitelli"
    Naples, Italy
  • Azienda USL-IRCCS Di Reggio Emilia
    Reggio Emilia, Italy
  • San Camillo Forlanini Hospitals
    Roma, Italy
  • Universita Cattolica del Sacro Cuore, University Hospital Gemelli
    Roma, Italy
  • IRCCS Fondazione Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Italy
  • National Cancer Centre Hospital East
    Chiba, Kashiwa, Japan
  • Hokkaido University Hospital
    Sapporo, Kita, Japan
  • Kyushu Cancer Center
    Fukuoka, Japan
  • Shikoku Cancer Center
    Matsuyama, Japan
  • Saitama Cancer Center
    Saitama, Japan
  • Shizuoka Cancer Center
    Shizuoka, Japan
  • Hallym University Sacred Heart Hospital
    Anyang, South Korea
  • Dong-A University Hospital
    Busan, South Korea
  • Haeundae Paik Hospital
    Busan, South Korea
  • Chungbuk National University Hospital
    Cheongju-si, South Korea
  • Jeonbuk National University Hospital
    Jeonju, South Korea
  • Gyeongsang National University Hospital
    Jinju, South Korea
  • Asan Medical Centre
    Seoul, South Korea
  • Chung-Ang University Hospital
    Seoul, South Korea
  • Kangbuk Samsung Hospital
    Seoul, South Korea
  • Korea University Anam Hospital
    Seoul, South Korea
  • Korea University Guro Hospital
    Seoul, South Korea
  • Seoul National University Bundang Hospital
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • SMG-SNU Boramae Medical Center
    Seoul, South Korea
  • The Catholic University of Korea - Seoul St. Mary's Hospital
    Seoul, South Korea
  • The Catholic University of Korea - Yeouido St. Mary's Hospital
    Seoul, South Korea
  • Yonsei University Health System - Gangnam Severance Hospital
    Seoul, South Korea
  • Yonsei University Health System - Severance Hospital
    Seoul, South Korea
  • Vall d'Hebron University Hospital
    Barcelona, Spain
  • Hospital Universitario de Navarra
    Pamplona, Spain
  • Hospital Clinico Universitario De Valencia
    Valencia, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, Taiwan
  • China Medical University Hospital (CMUH)
    Taichung, Taiwan
  • National Cheng Kung University Hospital
    Taipei, Taiwan
  • National Taiwan University Hospital (NTUH)
    Taipei, Taiwan
  • Taipei Veterans General Hospital (TPVGH)
    Taipei, Taiwan
09

References and documents

Publications

  • Lam LL, Pavlakis N, Shitara K, Sjoquist KM, Martin AJ, Yip S, Kang YK, Bang YJ, Chen LT, Moehler M, Bekaii-Saab T, Alcindor T, O'Callaghan CJ, Tebbutt NC, Hague W, Chan H, Rha SY, Lee KW, Gebski V, Jaworski A, Zalcberg J, Price T, Simes J, Goldstein D. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer. 2023 Feb 22;23(1):180. doi: 10.1186/s12885-023-10642-7. PubMed 36814222 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jan 2025, 44 months.

Results were first posted in Jun 2026, 1 year 4 months after primary completion.

Of 55 non-industry phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 108. This study's 44 months is below that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
May 10, 2021
StartActual
May 5, 2021
Primary completionActual
Jan 14, 2025
CompletionActual
Apr 30, 2025
Results first posted
Jun 10, 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04879368
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Collaborators
Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Responsible party
Sponsor
First posted
May 10, 2021
Start date
May 5, 2021
Primary completion
Jan 14, 2025
Completion
Apr 30, 2025
Results posted
Jun 10, 2026
Last update
Jun 10, 2026

Study contacts

Nick Pavlakis, Prof
study chair · AGITG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Regorafenib · Nivolumab

Start the discussion